On the public citation graph
Comparative Long and Short-Term Efficacy and Safety of Pertuzumab Plus Trastuzumab Versus Trastuzumab Monotherapy in Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Systematic Review and Meta-Analysis of Six Randomized Controlled Trials
0 signed · 22 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jamaoncol.2019.3692openalex-extracted
Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia
inferredcites →https://doi.org/10.1007/s10549-021-06387-1openalex-extracted
Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer
inferredcites →https://doi.org/10.1016/j.breast.2018.03.006openalex-extracted
HER2-positive breast cancer: Current and new therapeutic strategies
inferredcites →https://doi.org/10.1016/j.ejca.2010.10.013openalex-extracted
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
inferredcites →https://doi.org/10.1016/j.ejca.2017.10.021openalex-extracted
Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer
inferredcites →https://doi.org/10.1016/j.gendis.2018.05.001openalex-extracted
Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis
inferredcites →https://doi.org/10.1016/s1470-2045(16)00163-7openalex-extracted
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
inferredcites →https://doi.org/10.1038/s41467-021-26019-yopenalex-extracted
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial
inferredcites →https://doi.org/10.1038/s41467-024-45591-7openalex-extracted
Neoadjuvant–adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial
inferredcites →https://doi.org/10.1056/nejmoa1914609openalex-extracted
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
inferredcites →https://doi.org/10.1093/cid/cir073openalex-extracted
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
inferredcites →https://doi.org/10.1136/bmj.b2700openalex-extracted
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
inferredcites →https://doi.org/10.1158/1078-0432.ccr-19-3492openalex-extracted
Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis
inferredcites →https://doi.org/10.1158/1078-0432.ccr-22-1092openalex-extracted
Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis
inferredcites →https://doi.org/10.1177/1758835919833519openalex-extracted
HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
inferredcites →https://doi.org/10.1200/jco.2015.62.3488openalex-extracted
Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update
inferredcites →https://doi.org/10.21037/tbcr-24-31openalex-extracted
Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024
inferredcites →https://doi.org/10.3389/fonc.2022.894861openalex-extracted
Pertuzumab combined with trastuzumab compared to trastuzumab in the treatment of HER2-positive breast cancer: A systematic review and meta-analysis of randomized controlled trials
inferredcites →https://doi.org/10.6004/jnccn.2024.0035openalex-extracted
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
inferredcites →https://doi.org/10.3322/caac.21660openalex-snapshot
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.